Cargando…

First experiences in treatment of low-grade glioma grade I and II with proton therapy

BACKGROUND: To retrospectively assess feasibility and toxicity of proton therapy in patients with low-grade glioma (WHO °I/II). PATIENTS AND METHODS: Proton beam therapy only administered in 19 patients (median age 29 years; 9 female, 10 male) for low-grade glioma between 2010 and 2011 was reviewed....

Descripción completa

Detalles Bibliográficos
Autores principales: Hauswald, Henrik, Rieken, Stefan, Ecker, Swantje, Kessel, Kerstin A, Herfarth, Klaus, Debus, Jürgen, Combs, Stephanie E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527266/
https://www.ncbi.nlm.nih.gov/pubmed/23140402
http://dx.doi.org/10.1186/1748-717X-7-189
_version_ 1782253684346847232
author Hauswald, Henrik
Rieken, Stefan
Ecker, Swantje
Kessel, Kerstin A
Herfarth, Klaus
Debus, Jürgen
Combs, Stephanie E
author_facet Hauswald, Henrik
Rieken, Stefan
Ecker, Swantje
Kessel, Kerstin A
Herfarth, Klaus
Debus, Jürgen
Combs, Stephanie E
author_sort Hauswald, Henrik
collection PubMed
description BACKGROUND: To retrospectively assess feasibility and toxicity of proton therapy in patients with low-grade glioma (WHO °I/II). PATIENTS AND METHODS: Proton beam therapy only administered in 19 patients (median age 29 years; 9 female, 10 male) for low-grade glioma between 2010 and 2011 was reviewed. In 6 cases proton therapy was performed due to tumor progression after biopsy, in 8 cases each due to tumor progression after (partial-) resection, and in 5 cases due to tumor progression after chemotherapy. Median total dose applied was 54 GyE (range, 48,6-54 GyE) in single fractions of median 1.8 GyE. Median clinical target volume was 99 cc (range, 6–463 cc) and treated using median 2 beams (range, 1–2). RESULTS: Proton therapy was finished as planned in all cases. At end of proton therapy, 13 patients showed focal alopecia, 6 patients reported mild fatigue, one patient with temporal tumor localization concentration deficits and speech errors and one more patient deficits in short-term memory. Four patients did not report any side effects. During follow-up, one patient presented with pseudo-progression showing worsening of general condition and brain edema 1–2 months after last irradiation and restitution after 6 months. In the present MR imaging (median follow-up 5 months; range 0–22 months) 12 patients had stable disease, 2 (1) patients partial (complete) remission, one more patient pseudo-progression (differential diagnosis: tumor progression) 4 weeks after irradiation without having had further follow-up imaging so far, and one patient tumor progression approximately 9 months after irradiation. CONCLUSION: Regarding early side effects, mild alopecia was the predominant finding. The rate of alopecia seems to be due to large treatment volumes as well as the anatomical locations of the target volumes and might be avoided by using multiple beams and the gantry in the future. Further evaluations including neuropsychological testing are in preparation.
format Online
Article
Text
id pubmed-3527266
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35272662012-12-21 First experiences in treatment of low-grade glioma grade I and II with proton therapy Hauswald, Henrik Rieken, Stefan Ecker, Swantje Kessel, Kerstin A Herfarth, Klaus Debus, Jürgen Combs, Stephanie E Radiat Oncol Research BACKGROUND: To retrospectively assess feasibility and toxicity of proton therapy in patients with low-grade glioma (WHO °I/II). PATIENTS AND METHODS: Proton beam therapy only administered in 19 patients (median age 29 years; 9 female, 10 male) for low-grade glioma between 2010 and 2011 was reviewed. In 6 cases proton therapy was performed due to tumor progression after biopsy, in 8 cases each due to tumor progression after (partial-) resection, and in 5 cases due to tumor progression after chemotherapy. Median total dose applied was 54 GyE (range, 48,6-54 GyE) in single fractions of median 1.8 GyE. Median clinical target volume was 99 cc (range, 6–463 cc) and treated using median 2 beams (range, 1–2). RESULTS: Proton therapy was finished as planned in all cases. At end of proton therapy, 13 patients showed focal alopecia, 6 patients reported mild fatigue, one patient with temporal tumor localization concentration deficits and speech errors and one more patient deficits in short-term memory. Four patients did not report any side effects. During follow-up, one patient presented with pseudo-progression showing worsening of general condition and brain edema 1–2 months after last irradiation and restitution after 6 months. In the present MR imaging (median follow-up 5 months; range 0–22 months) 12 patients had stable disease, 2 (1) patients partial (complete) remission, one more patient pseudo-progression (differential diagnosis: tumor progression) 4 weeks after irradiation without having had further follow-up imaging so far, and one patient tumor progression approximately 9 months after irradiation. CONCLUSION: Regarding early side effects, mild alopecia was the predominant finding. The rate of alopecia seems to be due to large treatment volumes as well as the anatomical locations of the target volumes and might be avoided by using multiple beams and the gantry in the future. Further evaluations including neuropsychological testing are in preparation. BioMed Central 2012-11-09 /pmc/articles/PMC3527266/ /pubmed/23140402 http://dx.doi.org/10.1186/1748-717X-7-189 Text en Copyright ©2012 Hauswald et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hauswald, Henrik
Rieken, Stefan
Ecker, Swantje
Kessel, Kerstin A
Herfarth, Klaus
Debus, Jürgen
Combs, Stephanie E
First experiences in treatment of low-grade glioma grade I and II with proton therapy
title First experiences in treatment of low-grade glioma grade I and II with proton therapy
title_full First experiences in treatment of low-grade glioma grade I and II with proton therapy
title_fullStr First experiences in treatment of low-grade glioma grade I and II with proton therapy
title_full_unstemmed First experiences in treatment of low-grade glioma grade I and II with proton therapy
title_short First experiences in treatment of low-grade glioma grade I and II with proton therapy
title_sort first experiences in treatment of low-grade glioma grade i and ii with proton therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527266/
https://www.ncbi.nlm.nih.gov/pubmed/23140402
http://dx.doi.org/10.1186/1748-717X-7-189
work_keys_str_mv AT hauswaldhenrik firstexperiencesintreatmentoflowgradegliomagradeiandiiwithprotontherapy
AT riekenstefan firstexperiencesintreatmentoflowgradegliomagradeiandiiwithprotontherapy
AT eckerswantje firstexperiencesintreatmentoflowgradegliomagradeiandiiwithprotontherapy
AT kesselkerstina firstexperiencesintreatmentoflowgradegliomagradeiandiiwithprotontherapy
AT herfarthklaus firstexperiencesintreatmentoflowgradegliomagradeiandiiwithprotontherapy
AT debusjurgen firstexperiencesintreatmentoflowgradegliomagradeiandiiwithprotontherapy
AT combsstephaniee firstexperiencesintreatmentoflowgradegliomagradeiandiiwithprotontherapy